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Abstract
Background & Aims: Secretin induces bicarbonate-rich hydrocholeresis in healthy individuals, but not in untreated patients
with primary biliary cirrhosis (PBC). Ursodeoxycholic acid (UDCA) – the first choice treatment for PBC – restores the secretin
response. Compared with humans, secretin has poor effect in experimental normal-rat models with biliary drainage,
although it may elicit hydrocholeresis when the bile-acid pool is maintained. In view of the benefits of UDCA in PBC, we
used normal-rat models to unravel the acute contribution of UDCA (and/or taurine-conjugated TUDCA) for eliciting the
biliary secretin response.
Methods: Intravascular and/or intrabiliary administration of agonists and inhibitors was performed in normal rats with
biliary monitoring. Secretin/bile-acid interplay was analyzed in 3D cultured rat cholangiocytes that formed expansive cystic
structures with intralumenal hydroionic secretion.
Results: In vivo, secretin stimulates hydrocholeresis upon UDCA/TUDCA infusion, but does not modify the intrinsic
hypercholeretic effect of dehydrocholic acid (DHCA). The former effect is dependent on microtubule polymerization, and
involves PKCa, PI3K and MEK pathways, as shown by colchicine (i.p.) and retrograde biliary inhibitors. In vitro, while secretin
alone accelerates the spontaneous expansion of 3D-cystic structures, this effect is enhanced in the presence of TUDCA, but
not UDCA or DHCA. Experiments with inhibitors and Ca
2+-chelator confirmed that the synergistic effect of secretin plus
TUDCA involves microtubules, intracellular Ca
2+, PKCa, PI3K, PKA and MEK pathways. Gene silencing also demonstrated the
involvement of the bicarbonate extruder Ae2.
Conclusions: UDCA is conjugated in order to promote secretin-stimulated hydrocholeresis in rats through Ae2,
microtubules, intracellular Ca
2+, PKCa, PI3K, PKA, and MEK.
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Introduction
Primary bile generated at the canaliculi is fluidized and
alkalinized along the intrahepatic biliary tract, a process that is
normally stimulated by secretin [1,2]. In humans, secretin-
stimulated bile flow may account for up to 40% of the total bile
output from the liver. Previous in vivo experiments in an animal
model of infused normal rat with biliary drainage, together with
data obtained in cultured normal-rat cholangiocytes, indicated
that the Cl
2/HCO3
2 anion exchanger 2 (Ae2) mediates biliary
secretion of bicarbonate in response to secretin [3]. Bicarbonate
concentration then serves as an osmotic driving force for
aquaporin 1 to mediate the efflux of water, leading to increased
hydrocholeresis [4]. For secretin to exert these effects in normal
live rats we found that the bile-acid pool needs to be maintained
by, for instance, continuous infusion of taurocholic acid (TCA) [3].
Ursodeoxycholic acid (UDCA) is a more hydrophilic dihydroxy
bile acid that is considered to possess superior pharmacological
properties, being currently used as the first choice treatment for a
number of cholestatic liver diseases, particularly primary biliary
cirrhosis (PBC) [5–7]. Among numerous positive effects of UDCA
like its ability to increase the hydrophilicity in the pool of bile
acids, and its immunomodulatory and cytoprotective properties,
UDCA is known to stimulate bicarbonate-rich hypercholeresis in
humans [6,8]. The benefit of a hydrocholeresis that is particularly
rich in bicarbonate has recently been enlightened by the attractive
‘‘biliary bicarbonate umbrella’’ hypothesis [9,10]. Earlier positron-
emission tomography (PET) studies using labeled bicarbonate
showed that untreated PBC patients have impaired biliary
bicarbonate secretion in response to secretin, a defect that is
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[11]. On the other hand, untreated PBC patients exhibit
diminished expression of AE2 in the liver, and treatment with
UDCA appears to be associated with improved AE2 expression
[6,12,13].
Experiments carried out in normal-rat models with biliary
drainage indicate that UDCA, but not its taurine-conjugate
tauroursodeoxycholic acid (TUDCA), may stimulate the produc-
tion and canalicular secretion of S-nitrosoglutathione (GSNO),
which leads to hydrocholeresis in the biliary epithelium [14]. The
observation that infusion of TUDCA does not trigger the
production of GSNO but still promotes bicarbonate-rich hyperch-
oleresis prompted us to analyze the possible direct effects of
TUDCA versus UDCA on the biliary epithelium and the
relationship of those effects with secretin. Also we compared these
effects with the effect of dehydrocholic acid (DHCA) – known to
strongly promote canalicular bile flow and microtubule-indepen-
dent hypercholeresis [15] – in relation with secretin. Our findings
both in normal rats and in 3D-cultured cholangiocyte cystic
structures unraveled the crucial role of conjugation of UDCA for
its concerted action with secretin to promote hydrocholeresis. The
mechanisms involved in this concerted action include microtu-
bules and Ae2, as well as intracellular Ca
2+, protein kinase Ca
(PKCa), mitogen-activated protein kinases/extracellular-signal
regulated kinases (MAPK-ERK1/2) kinase (MEK or MAP2K),
phosphoinositide 3-kinase (PI3K), and protein kinase A (PKA)
signaling pathways.
Materials and Methods
Direct biliary monitoring in infused normal rat
Bile flow was monitored in our already described animal model
[3], in which normal live rats are intravenously infused with
secretin and/or bile acids, and the bile duct may receive different
inhibitors. Briefly, midline abdomen incision in anesthetized
normal male Wistar rats (,250 g) was followed by cannulation
of the common bile duct. Then the iliac vein was cannulated for
continuous infusion (2 mL/h) of 0.9% NaCl solution with 20 mM
of either UDCA, TUDCA (both from Sigma-Aldrich), or DHCA
(Calbiochem). Fifteen minutes after starting bile-acid infusion,
saline solutions (0.2 mL) with either the specific inhibitor of Ca
2+-
dependent (conventional) PKCa Go ¨6976 (Calbiochem; 1 mM), the
MEK inhibitor U0126 (Promega; 10 mM), or the PI3K inhibitor
wortmannin (Fluka Biochemika; 100 nM), were administered
intrabiliary (through retrograde fluxes) and let to stand in the bile
duct for 20 min. Meanwhile, a bolus of rat secretin (RayBiotech;
40 nmol) was infused in saline solution (0.12 mL) via the iliac vein
5 min after retrograde fluxes, and the biliary cannula was removed
15 min afterwards, bile being collected in 1.5-mL tubes for the first
5 min. In some rats microtubule polymerization was blocked by
colchicine (Sigma-Aldrich), administered intraperitoneally
(2.5 mg/kg b.w in 0.5 mL PBS) 150 min before bile-acid
infusions. The experimental protocol was approved by the
University of Navarra Animal Care Committee (approval ID:
065-09).
Cholangiocyte culture
Normal-rat cholangiocytes were obtained by isolating intrahe-
patic bile-duct units from male Wistar rats and culturing them on a
rat-tail collagen monolayer with an enriched DMEM/F-12
medium, as described for mouse cholangiocytes [16]. For 3D-
culture, clusters of rat cholangiocytes were grown between two
layers of type I rat tail collagen (1.5 mg/mL) plus 10% Matrigel
(both from BD Biosciences), and maintained in enriched DMEM/
F-12 medium. Under these conditions, clusters of cholangiocytes
spontaneously form cystic structures that expand over time as a
consequence of hydroionic secretion to the cyst lumen [17]. Cystic
structures were assessed in an inverted light microscope for
changes in their expansion in response to 1 mM secretin for
30 min, with or without the presence of 200 mM of bile acids
(UDCA, TUDCA and DHCA, as well as TCA). Positive effects
were further assessed in the presence of different inhibitors:
0.05 mM colchicine, 100 nM wortmannin, 10 mM U0126, 1 mM
Go ¨6976, 30 mM of the calcium chelator BAPTA (Sigma-Aldrich),
and 10 mM of the PKA inhibitor H89 (Sigma-Aldrich). Each
inhibitor was added 30 min before and during secretin stimulation
for additional 30 min. Cyst expansion was assessed as the
circumferential area of the cyst before and after the stimuli and/
or inhibition, with the Image J software (National Institutes of
Health, Bethesda, MD). Data obtained were expressed as a
percentage of cystic-area expansion.
Gene silencing
Small interfering RNA (siRNA) rAe2 (GGUGUGGACGA-
GUACAACGUU), against rat Ae2 or control siRNA (GGU-
GUGGACGAGUACAAUGUU), reported to target human but
not rat Ae2 [3], were added to the medium (50 nM each) 1 day
before monitoring the cystic structures, as previously reported
[18].
Statistics
Values are shown as mean 6 SD or SEM where indicated. The
nonparametric Mann-Whitney test was used when two groups
were compared. For more than two groups, the nonparametric
Kruskal-Wallis test followed by Dunns post-hoc test or parametric
ANOVA with Bonferroni post-hoc test were used. Differences were
considered statistically significant when two-tailed P values were
,0.05 (not adjusted).
Results
Effect of secretin on the bile flow in normal rats infused
with UDCA, TUDCA or DHCA
Secretin administration to normal rats infused with UDCA
increased the bile flow compared with baseline bile flow (i.e. in rats
without infusion of both secretin and bile acids, Fig. 1).
Replacement of unconjugated UDCA with taurine-conjugated
TUDCA resulted in similar secretin-stimulated bile flow versus
baseline values (Fig. 1). Neither UDCA, TUDCA nor secretin
alone significantly increased the bile flow (Fig. 1). As previously
reported in other animal models [19], infusion of normal rats with
DHCA alone induced hydrocholeresis (Fig. 1). However, DHCA-
induced choleresis was not affected by secretin (Fig. 1).
Effects of inhibitors on secretin-stimulated
hydrocholeresis in normal rats infused with UDCA or
TUDCA
Intraperitoneal injection of colchicine (an inhibitor of microtu-
bule polymerization and microtubule-dependent vesicle mobiliza-
tion) did not modify the basal bile flow (not shown), but did block
the secretin-stimulated bile flow in UDCA- and TUDCA-infused
animals (Fig. 2A–B). On the other hand, colchicine did not
significantly modify the increased bile flow observed in DHCA-
infused normal rats, regardless of secretin administration (Fig. 2C).
To elucidate the mechanism by which secretin stimulates the
bile flow in the UDCA- and TUDCA-infused normal rats,
intrabiliary administration of inhibitors was employed. We
TUDCA Involvement in Secretin Effect
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2+-dependent
kinase involved in processes of bile acid-dependent secretion) [20],
by using the inhibitor Go ¨6976. While intrabiliary administration
of Go ¨6976 alone did not affect baseline bile flow (data not shown),
it attenuated the stimulatory effect of secretin in the animals
infused with either UDCA or TUDCA (Fig. 2A–B). Go ¨6976,
however, did not diminish the bile-flow increases in the DHCA-
infused normal rats with and without secretin administration
(Fig. 2C).
We analyzed the role of two additional kinases, PI3K and
MEK, which are frequently involved in secretory processes in
cholangiocytes, through intrabiliary administration of wortmannin
and U0126, respectively. While neither wortmannin nor U0126
alone affected the baseline bile flow in normal rats (data not
shown), both inhibitors dampened down the increased bile flow in
the normal rats receiving secretin plus either UDCA or TUDCA
(Fig. 2A–B). On the other hand, none of these inhibitors
significantly diminished the bile-flow increases in the DHCA-
infused normal rats, regardless of secretin administration (Fig. 2C).
Effect of secretin on the cystic expansion of 3D-cultured
normal-rat cholangiocytes in the presence of bile acids
To directly analyze the secretin/bile-acids interplay in cholan-
giocytes we used the recently described model of cholangiocyte
cystic structures in 3D [17]. They expand spontaneously as a
consequence of hydroionic secretion to the cyst lumen, and
accelerate their expansion rate in the presence of secretin [17].
Indeed, we reproduced these findings and found that administra-
tion of secretin alone during 30 min accelerated the expansion of
cholangiocyte cystic structures (Fig. 3A–B). The cooperative effect
of bile acids on the in vitro secretin-stimulated hydrocholeresis was
then analyzed by adding either UDCA, TUDCA, or DHCA to the
culture medium. At the concentration of 200 mM, TUDCA was
found to further accelerate the secretin-stimulated cystic expan-
sion, while the presence of unconjugated UDCA in the culture
medium showed no concerted action with secretin (Fig. 3A–B).
TUDCA exerted its effect in a dose-dependent manner (Fig. S1).
Also, the effect of TUDCA was specific, as TCA (another taurine-
conjugated bile acid) did not exhibit any concerted action with
secretin (Fig. S2A–B). The presence in the culture medium of
200 mM DHCA (an unconjugated bile acid with intrinsic
choleretic effect in vivo) did not further accelerate the stimulatory
effect of secretin (Fig. 3A–B). And neither TUDCA, UDCA, nor
DHCA alone (in the absence of secretin) affected the spontaneous
baseline expansion of cholangiocyte cystic structures in our cell
culture conditions (Fig. 3A–B). Although higher concentrations of
bile acids were also employed, no positive effects were observed on
either spontaneous or secretin-stimulated cystic-structure expan-
sion (data not shown).
Effects of inhibitors on the expansion of 3D-cultured
cholangiocyte cystic structures in the presence of
TUDCA+secretin
In view of the blocking effects observed in vivo with colchicine,
we assessed the role of microtubule polymerization for the cystic-
structure expansion stimulated by secretin+TUDCA. While the
presence of colchicine in the culture medium did not modify the
baseline expansion (see Fig. S3A for the inhibitors alone), it
blocked the [secretin+TUDCA]-stimulated expansion of cystic
structures (Fig. 4; see Fig. S3B for representative images).
We also tested the role of intracellular Ca
2+ by adding BAPTA
(a chelator of intracellular Ca
2+)o rG o ¨6976 (the inhibitor of the
Ca
2+-dependent PKCa) to the culture medium. While neither
BAPTA nor Go ¨6976 alone affected the baseline cystic-structure
expansion, they both inhibited the cystic expansion stimulated by
the combination of secretin and TUDCA (Fig. 4).
Likewise, the involvement of PI3K, MEK, and PKA in
cholangiocyte cyst hydrocholeresis was tested by using their
respective inhibitors wortmannin, U0126, and H89. These
inhibitors each blocked the cystic expansion stimulated by the
combination of secretin and TUDCA (Fig. 4). On the other hand,
wortmannin, U0126, and H89 alone, i.e. in the absence of secretin
and TUDCA, were each found to stimulate the baseline expansion
of the cystic structures, suggesting non-specific effects of these
inhibitors.
Effects of Ae2 silencing on the expansion of 3D-cultured
cholangiocyte cystic structures
Finally, we analyzed (in an additional set of experiments) the
role of Ae2 (the Cl
2/HCO3
2 exchanger that mediates bicarbon-
ate secretion in normal-rat cholangiocytes) [3], for the hydrocho-
leresis stimulated by secretin+TUDCA in the cystic structures.
Control and rAe2 siRNAs were added to the culture medium 24 h
before the analysis of cystic hydroionic secretion. As previously
reported [17], under these conditions Cy3-labeled siRNAs can
directly enter the cholangiocytes (Fig. S4A). Although the presence
of control siRNA did not affect the cystic-structure expansion
stimulated by secretin and TUDCA, the presence of the siRNA
against Ae2 totally blocked cystic expansion under all circum-
stances (Fig. 5 and Fig. S4B).
Discussion
In the hepatobiliary tract, secretin acts in the cholangiocytes
(but not in the hepatocytes), stimulating bicarbonate-rich hydro-
choleresis [1]. Thus, secretin stimulation constitutes a feasible
maneuver to assess the health status of the biliary epithelium. In
fact, we previously showed with PET technology that untreated
PBC patients have defective biliary bicarbonate secretion in
response to secretin administration, a defect that is reversed in
patients receiving UDCA for several months [11]. Currently,
UDCA is the only approved therapy for PBC [5,7,8], and a
majority of PBC patients who have initiated the UDCA treatment
Figure 1. Secretin stimulates bile flow in normal rats infused
with UDCA and TUDCA. The choleretic effects of secretin, UDCA, or
TUDCA administered alone were not significant, while infusion of DHCA
alone stimulated the bile flow of normal rats, with no effect on the
secretin response. All relevant differences are indicated (with no
statistical difference between secretin-stimulated bile flows in UDCA-
and TUDCA-infused animals). Data are shown as mean 6 SD.
doi:10.1371/journal.pone.0028717.g001
TUDCA Involvement in Secretin Effect
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fewer complications and even normal life expectancy [5,7]. Our
present data using secretin stimulation in both in vivo and in vitro
normal-rat models unravel the crucial role of conjugation of
UDCA for its concerted action with secretin to promote
hydroionic secretion at the rat biliary epithelium. The mechanisms
involved in this concerted action include microtubules and Ae2, as
well as intracellular Ca
2+, PKCa, PI3K, MEK and PKA signal
transduction cascades (summarized in Fig. 6).
Our experimental model of infused normal rat with biliary
drainage allows for the analysis of the effects of intravascular and/
or intrabiliary administration of molecules over the bile flow [3].
In contrast to the rodent models with bile-ductal hyperplasia (like
the bile-duct ligated rat) in which secretin displays manifest biliary
effects, the model of normal rat with biliary drainage was shown to
require a maintenance of the bile acid pool (for instance through
continuous bile-acid infusion) for secretin to achieve significant
effects [3]. Here, our model of infused normal rat with biliary
drainage was highly convenient to explore in vivo the mechanisms
involved in the cooperative interplay between secretin and bile
acids, particularly UDCA and its taurine-conjugated form
TUDCA, at the biliary epithelium. To better dissect such a
cooperative interplay observed in vivo, we also used our recently
described in vitro model of 3D-cultured cholangiocyte cystic
structures [17,18]. These cystic structures expand spontaneously
over time as a consequence of secretion to the cyst lumen, and are
Figure 2. Increased bile flow in rats receiving secretin and either UDCA or TUDCA is dependent on microtubule polymerization,
PKC, PI3K and MEK. The increased bile flow in rats receiving secretin plus (A) UDCA or (B) TUDCA was blocked with intraperitoneal administration
of colchicine (an inhibitor of microtubule polymerization), intrabiliary administration of the Ca
2+-dependent PKCa inhibitor Go ¨6976, intrabiliar
wortmannin (a PI3K inhibitor), and intrabiliar U0126 (a MEK inhibitor). (C) On the other hand, the hydrocholeretic effect to DHCA was unaffected by
these inhibitors. Increases versus respective controls were calculated as indicated. Data are shown as mean 6 SD.
doi:10.1371/journal.pone.0028717.g002
TUDCA Involvement in Secretin Effect
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Accordingly, they were used to evaluate the concerted action of
bile acids with the primary secretin effect, further promoting the
hydroionic secretion of functional cholangiocytes.
While in vivo infusion of either UDCA or TUDCA allowed for
secretin to increase hydrocholeresis (Fig. 1), only TUDCA
positively cooperated with the primary effect of secretin in vitro,
accelerating the expansion rate of cholangiocyte cystic structures
versus secretin alone (Fig. 3). These data indicate that the biliary
hydrocholeretic effect observed with secretin in the UDCA-infused
rats involves conjugation of UDCA. In fact, before its canalicular
secretion, UDCA is normally conjugated with taurine and glycine
(mostly with taurine in the rat) [21], by the enzyme BAAT (bile
acid coenzyme A:amino acid N-acyltransferase) located in the
peroxisomes [22]. Previous reports indicated that conjugation is
relevant for the anticholestatic [23] and cytoprotective [24] effects
of UDCA in hepatocytes. Now, we show that conjugation of
UDCA is also needed for its cooperation in promoting the
hydrocholeretic effect of secretin in cholangiocytes. It should be
taken into account that when UDCA is clinically employed for the
treatment of cholestatic diseases, it is orally administered in the
unconjugated form, but once it reaches the liver through the portal
circulation, it is rapidly conjugated in the hepatocyte and secreted
to bile, the unconjugated UDCA being virtually undetectable in
bile.
In our in vitro model of cystic structures, both secretin and bile
acids reach cholangiocytes at their basolateral side. In our in vivo
model of UDCA-infused rats, however, the biliary drainage
Figure 3. TUDCA promotes secretin-stimulated expansion of 3D-cultured cholangiocyte cystic structures. (A) Representative images of
cystic structures incubated for 60 min in the presence or absence of bile acids (UDCA, TUDCA, or DHCA), and with secretin for the last 30 min. (B)
While secretin alone stimulated cystic expansion, such an expansion was further accelerated in the presence of TUDCA, but not in the presence of
UDCA or DHCA (which rather tended to block the stimulatory effect of secretin). Only comparisons of interest are indicated.
doi:10.1371/journal.pone.0028717.g003
TUDCA Involvement in Secretin Effect
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conjugated TUDCA reaches cholangiocytes at their apical side
only. In clinical settings like that of PBC patients treated
chronically with UDCA, a significant portion of the biliary-
secreted conjugated TUDCA may return to blood through the
enterohepatic circulation and reach also the basolateral side of
cholangiocytes (similarly to our in vitro model).
Before UDCA was widely used for the treatment of cholestatic
disorders, the semi-synthetic triketo bile acid DHCA was
considered a valid therapeutic approach because of its hyperch-
oleretic properties and low toxicity [19]. Our in vivo and in vitro
data indicate that the pronounced hypercholeretic effect of DHCA
in the rat is neither related to the cholangiocytes nor modulated by
secretin, being seemingly circumscribed to the hepatocytes. The
molecular mechanisms by which DHCA exerts its hypercholeretic
action remain unknown. In contrast to UDCA and TUDCA,
which promote tubule-vesicular transport in hepatocytes [6,25,26],
earlier studies have indicated that DHCA increases the canalicular
bile flow via a microtubule-independent mechanism [15].
Accordingly, it was not surprising that colchicine did not modify
the intrinsic and secretin-insensitive hydrocholeretic action of
DHCA in our in vivo model. On the other hand, the concerted
action of secretin and TUDCA to promote hydrocholeresis was
sensitive to colchicine. Previous data indicating that secretin effects
involve cAMP-stimulated vesicle mobilization [4,27] suggest that
colchicine targets mainly the action of secretin. Secretin signaling
transduction is also known to result in increased intracellular
Figure 4. The expansion of 3D-cultured cholangiocyte cystic structures stimulated by the combination of secretin and TUDCA is
dependent on microtubule polymerization, intracellular Ca
2+ and PKCa signaling, and PI3K, PKA and MEK pathways.
[TUDCA+secretin]-stimulated cystic expansion was sensitive to colchicine, the Ca2
+-chelator BAPTA, Go ¨6976, wortmannin, U0126 and the PKA-
inhibitor H89. Cystic expansion is expressed as percentage of the area at the end of the experiment (60 min) versus initial area (at time 0). Data are
shown as mean 6 SEM.
doi:10.1371/journal.pone.0028717.g004
Figure 5. The bicarbonate extruder Ae2 is involved in the
concerted hydrocholeretic effect of TUDCA and secretin. While
the presence of control siRNA had no effect on the expansion rate of
3D-cultured cholangiocyte cystic structures stimulated by secretin alone
or combination of secretin and TUDCA (left), the specific rAe2 siRNA
against rat Ae2 mRNA blocked all stimulatory effects (right). Data are
shown as mean 6 SEM.
doi:10.1371/journal.pone.0028717.g005
TUDCA Involvement in Secretin Effect
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finding that the PKA inhibitor H89 blocked the accelerated
hydroionic expansion of cholangiocyte cystic structures in the
presence of secretin+TUDCA was as expected.
PKA signaling may positively interact with other signal
transduction cascades like Ca
2+ signaling and activation of Ca
2+-
dependent PKCa, which appears to be closely associated with the
effects of TUDCA in the hepatocytes [6] and cholangiocytes [29].
Thus, a cooperative mechanism involving PKA and Ca
2+-
dependent PKCa was recently described for the hepatocellular
effects of TUDCA in a model of taurolitocholate-induced
canalicular cholestasis [20], in which a seemingly permissive
PKA activity appears to be associated with a crucial PKCa activity
for the anticholestatic action of TUDCA. A similar scenario may
occur in the cholangiocytes for TUDCA to promote the
hydrocholeretic effect of secretin. Our in vivo and in vitro data
showing that the PKCa inhibitor Go ¨6976 blocks the [TUDCA+-
secretin]-stimulated hydroionic secretion, support the role of
PKCa for the cooperative action of TUDCA in these biliary
cells. The effect of the intracellular-Ca
2+ chelator BAPTA blocking
the TUDCA promotion of secretin-stimulated expansion of
cholangiocyte cystic structures further corroborate the role of
Ca
2+ signaling.
In addition to Ca
2+/PKCa signaling, other signaling pathways
like MAPK/MEK and PI3K have previously been associated with
the effects of TUDCA in both hepatocytes [6] and cholangiocytes
[29]. TUDCA was found to prevent the loss of bile ducts and
restore a deficient hydrocholeretic response to secretin in rats with
simultaneous bile duct ligation and vagotomy, and these effects
were associated not only with increased intracelullar Ca
2+ and
stimulated PKCa, but also with activation of MAPK and PI3K
cascades [29]. On the other hand, TUDCA was shown in an
isolated perfused rat liver (IPRL) model to stimulate ATP release
into bile [30]. Biliary ATP may then activate P2Y receptors in
cholangiocytes inducing a Ca
2+/PKCa/PI3K-dependent secre-
tion of Cl
2 [31,32], which ultimately can be exchanged with
HCO3
2 leading to bicarbonate-rich hydrocholeresis. Our in vivo
and in vitro findings indicate that inhibition of MEK (with U0126)
and PI3K (with wortmannin) blocks the cooperative effect of
TUDCA for secretin-stimulated hydrocholeresis.
Both in our model of normal rats with biliary drainage and
maintained bile-acid pool [3], and in rats with ductal hyperplasia
[2], secretin-stimulated hydrocholeresis has been shown to be
dependent on the Cl
2/HCO3
2 exchange, a transport activity
which in rat cholangiocytes is mediated by Ae2 [3,16]. Here we
confirmed that Ae2 also participates in the hydroionic secretion
that expands our 3D-cultured cholangiocyte cystic structures
(Fig. 5). In fact, our findings with Ae2 silencing strongly suggest that
the cyst expansion stimulated by TUDCA and/or secretin entails
bicarbonate-rich hydroionic secretion into the cyst lumen.
As summarized in Fig. 6, our in vivo and in vitro data indicate that
secretin-stimulated hydrocholeresis in normal rats infused with
UDCA involves, at least partially, taurine-conjugation and
subsequent TUDCA-secretin interaction in cholangiocytes results
in activation of PKCa, PI3K, MEK and PKA pathways.
Moreover, the bicarbonate extruder Ae2 is also involved in the
hydrocholeretic effect. Our findings may enable a better
understanding of the benefits of UDCA for the restoration of the
response to secretin in patients with PBC. Together with the
recent reports that unconjugated UDCA stimulates canalicular
secretion of GSNO and biliary ATP release [14], and that
norUDCA/ and/or TnorUDCA might represent a complement
to UDCA therapies [23], our present mechanistic data may favor
the design of new therapeutic approaches to improve the
functionality of the biliary epithelium in patients with cholestatic
disorders. Indeed, two pilot studies were performed during the
nineties in some few patients with PBC which suggested that
treatment with TUDCA might be of benefit versus unconjugated
UDCA alone [33,34]. And previous reports indicated that dietary
taurine supplementation increases the proportion of taurine-
conjugation in bile [35,36]. Taurine supplementation could
therefore be considered to possibly modulate the therapeutic
properties of UDCA/TUDCA in PBC. It may be noticed that
taurine supplementation is currently being proposed as potentially
adjuvant for the treatment of different pathologies such as diabetes
mellitus and its complications, although this is based on a series of
Figure 6. Mechanisms proposed for the TUDCA-mediated
secretin-stimulated bile flow in the normal rat. The diagrams
summarize the proposed mechanisms for the concerted action of UDCA
and secretin that stimulates further the hydrocholeresis in the normal-
rat biliary epithelium: UDCA is conjugated with taurine in the
hepatocytes and secreted to bile as TUDCA, which may directly access
the apical side of cholangiocytes (as well as the basolateral side in the
case of an intact animal with enterohepatic circulation). In cholangio-
cytes, TUDCA may favor the action of secretin through modulation of
intracellular Ca2
+ levels, and PKCa and PI3K activation. MEK and cAMP-
dependent pathways as well as mobilization of vesicles appear to be
also involved. Ae2 has a crucial role for the secretin-stimulated
bicarbonate-rich hydrocholeresis by acting as the ultimate extruder of
bicarbonate through Cl
2/HCO3
2 exchange. Neither DHCA nor un-
conjugate UDCA may exert any of these acute effects on the biliary
epithelium, and they promote hydrocholeresis via different mecha-
nisms.
doi:10.1371/journal.pone.0028717.g006
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Supporting Information
Figure S1 TUDCA accelerates the secretin-stimulated
expansion of 3D-cultured cholangiocyte cystic structures
in a dose-dependent manner. (A) Representative images of
cystic structures in the presence of different doses of TUDCA (i.e.
0, 50, 100 and 200 mM) during 60 min, and with secretin for the
last 30 min. (B) The presence of TUDCA favored in a dose-
dependent manner the stimulatory effect of secretin on cyst
expansion. Data are shown as mean 6 SEM.
(TIF)
Figure S2 Taurocholic acid (TCA) did not further
promote the secretin-stimulated expansion of 3D-cul-
tured cholangiocyte cystic structures. (A) Representative
images of cystic structures incubated in the presence of TCA
during 60 min, and with secretin for the last 30 min. (B) The
presence of TCA did not accelerate the stimulatory effect of
secretin on cyst expansion. Data are shown as mean 6 SEM.
(TIF)
Figure S3 Effect of different inhibitors on the expansion
of 3D-cultured cholangiocyte cystic structures. (A) Rep-
resentative images of cystic structures incubated for 60 min with
TUDCA, and with secretin for the last 30 min, either in the
presence or the absence of inhibitors. (B) None of the inhibitors
blocked the spontaneous expansion of cystic structures; data are
shown as mean 6 SEM.
(TIF)
Figure S4 Knockdown experiments with siRNA indicate
that Ae2 is involved in the expansion of 3D-cultured
cholangiocyte cystic structures. (A) Representative images
showing that siRNAs are internalized in cholangiocyte cystic
structures: left, light microscopy image; right, fluorescence image of
an internalized Cy3-labeled siRNA in red color, merged with the
image on the left (artificially colored in green). (B) Representative
images of cholangiocyte cystic structures previously incubated for
24 hours with either control siRNA (an siRNA against human Ae2
mRNA which does not target rat Ae2 mRNA), rAe2 siRNA
(against rat Ae2 mRNA), or none siRNA. Cystic structures were in
the presence of TUDCA for 60 minutes, being supplemented with
secretin for the last 30 minutes.
(TIF)
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